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With more than 6000 patients treated and with 70% to 75% ofthese patients having a significant improvement in theirangina symptoms, one would think that the mechanismwhereby transmyocardial laser revascularization (TMLR)achieves its effect would be well understood. Of the manypossible mechanisms, including angiogenesis, channel pa-
tency, alterations of ventricular compliance, placebo effect, and denervation, it is the
latter that is the most difficult to prove or disprove. Clinical studies have indirectly
demonstrated that denervation does not play the primary role, a virtue of improve-
ment in perfusion, as demonstrated by nuclear spec scans and positron emission
tomograpic scans.1-5 Additionally, functional improvement with dobutamine stress
echocardiography6 and cine magnetic resonance imaging7 also indicates that dener-
vation is not the contributing mechanism. Furthermore, there is no significant
increase in the number of acute myocardial infarctions postoperatively, despite a
significant increase in exercise tolerance and activity levels.
In this issue, Minisi and associates8 have reported on an elegant set of experi-
ments designed to evaluate the effect of TMLR on reflexes mediated by left
ventricular receptors with sympathetic afferent fibers. Their results indicate that
TMLR does not acutely interrupt the afferent nerves, which transmit the perception
of anginal pain. These results are somewhat different from others that have been
reported, and this is due to Minisi and colleagues’ efforts to isolate the reflex
responses by using an animal preparation with sinoaortic denervation and vagot-
omy. As a result, they were also able to demonstrate that the reflex circuitry was
completely intact after TMLR. However, as the authors note, a major limitation of
this study is that these results are from normal canine myocardium and may not be
applicable to ischemic myocardium in human subjects. It does demonstrate that the
amount of damage inflicted by TMLR is not enough to denervate normal myocar-
dium.
The question of the extent of laser-induced injury and the ensuing response is an
important one. Recently, attempts to perform laser revascularization percutaneously
with a catheter have met with mixed results.9-11 In fact, a placebo-controlled trial has
demonstrated no benefit of percutaneous myocardial laser revascularization.11 The
revascularization that can be achieved percutaneously is limited because of the
delivery of the laser energy to a very thin layer of the subendocardium (2-3 mm) and
the difficulty with navigating the catheter within the ventricle to provide an adequate
distribution of the laser treatment. One other factor that may play a role is the type
of laser light that is used. Minisi and associates have used a holmium:YAG laser.
This laser is delivered through a fiber, which is manually advanced through the
myocardium. However, it is unknown whether the injury created is principally
caused by a mechanical effect of the fiber or caused by laser ablation. In the beating
heart it is impossible to ensure that a fiber pushed by hand is advancing behind the
wave of laser ablation. It would therefore be of interest to perform further experi-
ments, not only in an ischemic model but also using the fiber alone or using other
types of laser light that are not dependent on fiber delivery (for example, carbon
dioxide) to confirm their results and provide clinical correlation. This difference in
laser light has become clinically apparent over the long term because those treated
with a holmium:YAG laser have had a significant increase in angina over 3 years
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after treatment.12 In contrast, patients treated with carbon
dioxide TMLR have continued angina relief over 5 years
after treatment.13
Demonstrating that TMLR does not denervate the heart
is an important piece of the mechanistic puzzle.
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